Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BOLT - Bolt Biotherapeutics, Inc.
Market Cap 49.16M P/E - EPS this Y 21.60% Ern Qtrly Grth -
Income -71.29M Forward P/E -0.80 EPS next Y 11.90% 50D Avg Chg -13.00%
Sales 7.2M PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.31 EPS next 5Y - 52W High Chg -51.00%
Recommedations 1.70 Quick Ratio 6.53 Shares Outstanding 37.97M 52W Low Chg 10.00%
Insider Own 6.57% ROA -23.01% Shares Float 20.79M Beta 0.71
Inst Own 61.44% ROE -45.02% Shares Shorted/Prior 1.64M/1.65M Price 1.30
Gross Margin - Profit Margin - Avg. Volume 144,527 Target Price 4.83
Oper. Margin -719.26% Earnings Date Nov 9 Volume 28,668 Change -1.52%
Healthcare | Biotechnology | United States
About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Bolt Biotherapeutics, Inc. News
12/05/23 Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
11/20/23 Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?
11/09/23 Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
07:00 AM Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
10/24/23 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
10/23/23 Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
10/18/23 Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
10/17/23 Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
10/16/23 Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
09/28/23 Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
09/12/23 Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
09/05/23 Bolt Biotherapeutics to Participate in September Investor Conferences
08/09/23 Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations
03:10 PM Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
08/03/23 Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
07/31/23 Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
06/13/23 Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
05/30/23 BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
05/25/23 Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
05/11/23 Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
BOLT Chatroom

User Image tickeron Posted - 17 hours ago

What is the best stock to buy right now? Pick the best $AMP.X vs. $BOLT vs. $XLM.X. #amp https://srnk.us/go/4934117

User Image SpyLover Posted - 1 day ago

$BOLT Crazy, good news, and cash on hand, but no one is buying. Added here.

User Image tickeron Posted - 1 day ago

Which stock is the best to invest? Compare $AMP.X vs. $BOLT vs. $XLM.X. #amp https://srnk.us/go/4933133

User Image tickeron Posted - 3 days ago

If you have $AMP.X or $BOLT or $XLM.X in your portfolio, pay attention! #amp https://srnk.us/go/4931900

User Image MarketBeatInsiderTrades Posted - 5 days ago

Bolt Biotherapeutics Director Edgar Engleman Sells $23,482.55 in $BOLT www.marketbeat.com/stocks/NASDAQ/BOLT/insider-trades/

User Image cctranscripts Posted - 5 days ago

Bolt Technology Corporation director just disposed of 148,884 shares https://www.conferencecalltranscripts.org/summary/?id=12756900 $BOLT

User Image stockilluminati Posted - 5 days ago

$BOLT https://www.stockilluminati.com/bolt/filings.php - Bolt Biotherapeutics, Inc. - Common Stock files form 4 today, check out the details.

User Image abc12332 Posted - 11/28/23

$BOLT Anyone here following this that has been for awhile and understands the science? I’m new to this taking a small long position. 1001 looks like it is very active alone and with pertuzumab in HER2 pos breast cancer. Phase 2 trials continuing, large cash runway, no debt, etc. What is the reason there’s so little interest? What milestones did they miss in the past that tanked the share price? Is management suspect in their focus on maximizing shareholder value? Any information positive or negative appreciated.

User Image tickeron Posted - 11/27/23

A.I.dvisor made a bearish call on $BOLT, netting in a 11.73% gain over 1 week https://srnk.us/go/4925945

User Image mingdalee1982 Posted - 11/24/23

@abc12332 don't buy $BOLT, they failed in their adc bdc drug. Miller is just the director, he can't decide anything.

User Image tickeron Posted - 11/23/23

This is amazing! What do you think? $BOLT RSI Indicator left the oversold zone. View odds of downtrend. https://srnk.us/go/4922832

User Image cctranscripts Posted - 11/22/23

Bolt Technology Corporation director just disposed of 1,943 shares https://www.conferencecalltranscripts.org/summary/?id=12733685 $BOLT

User Image stockilluminati Posted - 11/22/23

$BOLT https://www.stockilluminati.com/bolt/filings.php - Bolt Biotherapeutics, Inc. - Common Stock files form 4 today, check out the details.

User Image cctranscripts Posted - 11/22/23

Major owner of Bolt Technology Corporation just disposed of 3,400 shares https://www.conferencecalltranscripts.org/summary/?id=12733591 $BOLT

User Image keepbuying Posted - 11/22/23

$LPTX squeeze just getting started- Friday should be fun $NXTC $BOLT

User Image tickeron Posted - 11/22/23

How does this affect your portfolio? $BOLT RSI Indicator left the oversold zone. View odds of downtrend. https://srnk.us/go/4921557

User Image keepbuying Posted - 11/21/23

@Vladdd90 if you are looking for for others w similar profiles below cash and data milestones coming soon look at $NXTC and $BOLT $EQ $ADVM

User Image MarketBeatInsiderTrades Posted - 11/21/23

Bolt Biotherapeutics Major Shareholder Vivo Capital Viii, Llc Sells $50,324.00 in $BOLT www.marketbeat.com/stocks/NASDAQ/BOLT/insider-trade

User Image MarketBeatInsiderTrades Posted - 11/21/23

Bolt Biotherapeutics Major Shareholder Vivo Capital Viii, Llc Sells $14,400.00 in $BOLT www.marketbeat.com/stocks/NASDAQ/BOLT/insider-trade

User Image insiderbuyingselling Posted - 11/21/23

$BOLT new insider selling: 49173 shares. http://insiderbuyingselling.com/?t=BOLT

User Image cctranscripts Posted - 11/20/23

Bolt Technology Corporation director just disposed of 49,173 shares https://www.conferencecalltranscripts.org/summary/?id=12725706 $BOLT

User Image risenhoover Posted - 11/20/23

Insider Edgar Engleman reports selling 49,173 shares of $BOLT for a total cost of $45,675.45 https://fintel.io/n/us/bolt/engleman-edgar?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider

User Image stockilluminati Posted - 11/20/23

$BOLT https://www.stockilluminati.com/bolt/filings.php - Bolt Biotherapeutics, Inc. - Common Stock files form 4 today, check out the details.

User Image cctranscripts Posted - 11/20/23

Major owner of Bolt Technology Corporation just disposed of 86,054 shares https://www.conferencecalltranscripts.org/summary/?id=12725668 $BOLT

User Image risenhoover Posted - 11/20/23

Insider Vivo Capital VIII, LLC reports selling 86,054 shares of $BOLT for a total cost of $79,933.22 https://fintel.io/n/us/bolt/vivo-capital-viii?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider

User Image Johnny7777 Posted - 11/20/23

$BOLT aded here. 38M OS makes $33M mcap with $141M cash on hand. Cashburn appx. $18M/Q. BDC-1001 and BDC-3042 data expected in 2024. Gl

User Image keepbuying Posted - 11/20/23

$LPTX data coming soon - check out $NXTC and $bolt both are way below cash and data coming very soon too

User Image goodmorningwallstreet Posted - 11/15/23

$BOLT on watch… B/O

User Image mo14 Posted - 11/14/23

$BOLT Been following this for a month or so and noticed this doesn’t drop down bad like i would expect with the low volume and how markets were last month. any longs here care to share if there is any news pending for the remaining year? Thanks in advance.

User Image Last10K Posted - 11/09/23

Last10K highlighted 33 positive and negative remarks in the $BOLT 10-Q filed today. See them in the Quarterly Report: https://last10k.com/sec-filings/BOLT/0000950170-23-062048.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=sentiment&utm_term=bolt

Analyst Ratings
HC Wainwright & Co. Buy Aug 8, 23
HC Wainwright & Co. Buy Aug 3, 23
HC Wainwright & Co. Buy Jun 5, 23
HC Wainwright & Co. Buy May 26, 23
SVB Leerink Outperform May 12, 23
HC Wainwright & Co. Buy May 12, 23
HC Wainwright & Co. Buy Mar 30, 23
Morgan Stanley Equal-Weight Jan 24, 23
HC Wainwright & Co. Buy Oct 4, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ENGLEMAN EDGAR Director Director Nov 29 Sell 0.88 148,884 131,018 251,522 12/01/23
ENGLEMAN EDGAR Director Director Nov 21 Sell 0.9 1,943 1,749 269,587 11/22/23
Vivo Capital VIII, LLC 10% Owner 10% Owner Nov 21 Sell 0.9 3,400 3,060 111,662 11/22/23
ENGLEMAN EDGAR Director Director Nov 16 Sell 0.94 49,173 46,223 269,823 11/20/23
Vivo Capital VIII, LLC 10% Owner 10% Owner Nov 16 Sell 0.94 86,054 80,891 113,119 11/20/23
Novo Holdings A/S 10% Owner 10% Owner Jul 13 Sell 2.00 800,000 1,600,000 3,703,991 07/15/22
Perez Edith A. Chief Medical Office.. Chief Medical Officer Dec 22 Option 2.8 35,714 99,999 37,042 02/01/22
Perez Edith A. Chief Medical Office.. Chief Medical Officer Dec 22 Buy 10.65 1,328 14,143 1,328 02/01/22